Surrozen
Tracked across 1 events · 7 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Surrozen, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. United States — Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment…
Impact: Surrozen is the developer of SZN-8141 and the submitter of the IND. This milestone advances its lead candidate toward clinical trials, potentially enhancing its pipeline value, though the stock saw a slight decline.
Sep 08, 2026 · 7 articles
100
Surrozen submitted IND application United States — Food and Drug AdministrationSurrozen submits IND for SZN-8141
ERGEN INTELLIGENCE
Track Surrozen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard